Clinical trials: Hepatitis; Epidemic
Chronic Hepatitis B, Chronic Hepatitis C
Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography
This is a multi-center cohort study in which the Real-time Tissue Elastography® measurements will predict prospectively the incidence of hepatocellular carcinoma, the incidence and severity of gastroesophageal varices ascites and…
- Trial name
- PICTURE (NCT01360892)
- Where
- Japan
- Volunteers
- 1,000 people
- Sponsor
- Kindai University
Hepatitis C
Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
The purpose of this study is to evaluate the efficacy and safety of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV) in treatment-experienced Black/African American and…
- Trial name
- NCT01467492
- Testing
- Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a
- Where
- 27 sites in United States
- Volunteers
- 121 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Autoimmune Hepatitis
ADCC Mediated B-Cell dEpletion and BAFF-R Blockade
VAY736 dose testing; VAY736 efficacy and safety testing.
- Trial name
- AMBER (NCT03217422)
- Testing
- VAY736
- Where
- 28 sites in United States, Argentina and 8 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Acute-On-Chronic Liver Failure, Alcoholic Hepatitis
A-TANGO Phase 2 Study
The purpose of this research is to know if a new combination of drugs (TAK-242 and G-CSF) in combination with standard therapy for acute-on-chronic liver failure (ACLF) is more effective than standard therapy for ACLF treatment…
- Conditions
- Acute-On-Chronic Liver Failure, Alcoholic Hepatitis, Liver Cirrhosis, Alcoholic
- Trial name
- A-TANGO (NCT06890039)
- Testing
- TAK-242, G-CSF (Filgrastim)
- Where
- United Kingdom
- Volunteers
- 78 people
- Sponsor
- Yaqrit Ltd
Hepatitis C
Identifying the Gaps in the Diagnosis and Management of Hepatitis C
The purpose of this study is to identify the gaps in diagnosing and managing hepatitis C infected patients so that interventions can be targeted to address these problem areas in order to optimize care of these patients.
- Trial name
- NCT00976781
- Where
- 2 sites in United States
- Sponsor
- Henry Ford Health System
Hepatitis C, Chronic
Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)
Based on previous experience with peginterferon alfa-2b/ribavirin in combination with boceprevir, the combination with peginterferon alfa- 2a/ribavirin and boceprevir is expected to be safe and well tolerated.
- Trial name
- NCT00845065
- Testing
- Boceprevir, Peginterferon alfa-2a, Ribavirin
- Volunteers
- 202 people
- Sponsor
- Merck Sharp & Dohme LLC
CKD With Hepatitis C
Safety and Efficacy of Sofosbuvir Based Antiviral Regimen for Treating Hepatitis C in Patients With Moderate to Advanced Chronic Kidney Disease and Patients Receiving Renal Replacement Therapy
All patients with chronic kidney disease (stages 3, 4 and 5) and chronic dialysis patients with HCV infection attending nephrology and Hepatology OPD or getting outpatient dialysis at the dialysis unit of ILBS.
- Trial name
- NCT02563665
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatitis B, Pertussis
Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012)
This is a multicenter extension study of two European randomized, double-blind studies (V419-007 and V419-008). It describes long-term persistence of hepatitis B and pertussis antibody responses in healthy 4- to 5 year old…
- Trial name
- NCT02759354
- Testing
- Blood Sample
- Volunteers
- 754 people, healthy volunteers welcome
- Sponsor
- MCM Vaccines B.V.
Hepatitis C
Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)
Acute hepatitis C is a liver disease related to a virus: hepatitis C virus (HCV). The type of Hepatitis C Virus present in Egypt (genotype 4), has the reputation to respond poorly to treatment at the chronic hepatitis stage.
- Trial name
- NCT00158522
- Testing
- pegylated interferon alpha2a
- Where
- Egypt
- Volunteers
- 31 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis B, Neoplasms
A Study to Investigate Whether the Immediate Use or Deferred Use of an Anti-viral Drug Lamivudine Will Help to Better Safe-guard the Delivery of Chemotherapy in Patients With Cancer Who Are Also Hepatitis B Carriers
Patients with non-lymphoma and non-leukaemia cancer who are also hepatitis B carriers will have a risk of hepatitis B reactivation during chemotherapy.
- Trial name
- NCT00516945
- Testing
- Lamivudine
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Hospital Authority, Hong Kong
Acute Cholestatic Hepatitis
Emergent Laparoscopic Cholecystectomy With ICG Cholangiography
A consecutive case series report to share our experience in surgical outcome of patients who underwent emergency laparoscopic cholecystectomy guided by indocyanine green (ICG) fluorescence.
- Trial name
- ELG-ICGC (NCT06549881)
- Testing
- emergency laparoscopic cholecystectomy guided by indocyanine green (ICG) fluorescence
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Peking Union Medical College Hospital
Hepatitis C, Deglutition Disorders
Bioequivalence Study of Crushed Elbasvir/Grazoprevir Compared to the Whole Tablet
Elbasvir/grazoprevir (Zepatier®) is a once-daily tablet for the treatment of chronic hepatitis C virus (HCV) GT1a, 1b or 4 infection containing the NS5A inhibitor elbasvir (ELB) 50 mg and the NS3/4A protease inhibitor grazoprevir…
- Trial name
- CRUSADE-2 (NCT03817619)
- Testing
- Zepatier whole tablet, Zepatier crushed tablet
- Where
- Netherlands
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Alcohol Use Disorder, Alcoholic Hepatitis
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
Given the severe consequences of alcohol relapse following liver transplantation for alcoholic hepatitis (AH-LT), it is critical to accurately identify alcohol use and implement alcohol interventions early in the post-transplant…
- Trial name
- NCT03845205
- Testing
- Integrated AUD Treatment
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Liver Failure, Acute on Chronic
Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
Acute on chronic liver failure (ACLF) is a distinct entity encompassing the acute deterioration of liver function, culminating in multiple organs failure and high short-term mortality.
- Trial name
- Ch-CANONIC (NCT02457637)
- Testing
- Standary therapy
- Where
- 16 sites in China
- Volunteers
- 2,600 people
- Sponsor
- Hai Li
HIV Infections, Hepatitis B
Treatment of Hepatitis in Patients Who Are Triple-Infected With HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV)
This study will investigate the safety and effectiveness of using adefovir dipivoxil (ADV), pegylated interferon (PEG-INF), and ribavirin (RBV) in patients triple-infected with hepatitis B virus (HBV), hepatitis C virus (HCV)…
- Conditions
- HIV Infections, Hepatitis B, Hepatitis C
- Trial name
- NCT00051077
- Testing
- Adefovir dipivoxil, Peginterferon-alfa-2A, Ribavirin
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis b
Pradefovir Treatment for the Patients With Chronic Hepatitis B Virus Infections: a Phase3 Study
This is a phase three study to evaluate the safety and efficacy of Pradefovir treatment in chronic hepatitis B patients. Subject will be randomized to Pradefovir group and TDF group at a ratio of 2:1.
- Trial name
- NCT04543565
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Chronic Hepatitis C
First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
This randomized, double-blind, placebo-controlled, 3-part study will assess the safety, tolerability, and pharmacokinetics of orally administered AL-335 in healthy volunteers (HV) and subjects with CHC infection.
- Trial name
- NCT02339207
- Testing
- AL-335
- Where
- 3 sites in France, Georgia and 1 more
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Hepatitis C
Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period
Using European data from patients included in the Named Patient Program (NPP) and from the early post-marketing authorization period, the present study aims to describe patient characteristics and to describe the effectiveness of…
- Trial name
- NCT02531269
- Where
- Switzerland
- Volunteers
- 249 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
VX-950-TiDP24-C133 - A Phase I Study Investigating the Interaction Between Telaprevir and Escitalopram
The purpose of this study is to investigate the effect of steady-state telaprevir (TVR) 750 mg q8h (3 times a day, every 8 hours) on the steady-state pharmacokinetics of escitalopram 10 mg q.d. (once a day), and vice versa.
- Trial name
- NCT00933894
- Testing
- Telaprevir; Escitalopram
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA
Hepatitis B, Chronic
REALM China Extension Study
The purpose of this study is to conduct an investigator initiated observational study to continue to follow up the China subset of study participants for another 5 years after they complete participation in the REALM Study
- Trial name
- NCT02974829
- Testing
- follow-up
- Where
- 50 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.